Argen X SE ADR (ARGX): Next-Year EPS Estimate 36.04%
As of 2026-11-12, Argen X SE ADR (ARGX) has a next-year EPS growth estimate of 36.04%. Featured in 3 EPS revision reports, most recently on 2026-08-20.
On 2026-11-12, analyst consensus for ARGX's next-year EPS growth shifted from 36.16% to 36.04% — a negative change of 0.12 percentage points. Current-year growth is projected at 40.57%.
What's Driving This
ARGX’s stock rise is primarily explained by the 2026-10-20 analyst upgrade to next-year EPS growth, from 32.77% to 32.79% (+0.02 pp). No provided headline clearly connects to that revision; recent news instead focuses on a Vyvgart Sjögren trial setback and stock declines. The data do
Generated 2026-10-29 from news as of 2026-10-29
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 36.04%
- EPS growth this year
- 40.57%
- EPS next quarter (est)
- $8.08
- Last price
- $981.33
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-11-12 | 36.04% | 40.57% | $8.08 | $981.33 |
| 2026-11-11 | 36.16% | 40.57% | $8.08 | $977.58 |
| 2026-11-10 | 31.15% | 45.14% | $8.04 | $971.55 |
| 2026-11-09 | 31.15% | 45.14% | $8.04 | $962.27 |
| 2026-11-07 | 30.57% | 45.30% | $8.04 | $927.21 |
| 2026-11-06 | 30.57% | 45.30% | $8.04 | $927.21 |
| 2026-11-05 | 30.72% | 45.46% | $8.04 | $894.77 |
| 2026-11-04 | 30.72% | 45.46% | $8.04 | $931.38 |
| 2026-11-03 | 30.72% | 45.46% | $8.04 | $901.12 |
| 2026-11-02 | 30.05% | 45.69% | $8.08 | $874.97 |
| 2026-10-31 | 30.89% | 47.03% | $8.04 | $892.87 |
| 2026-10-30 | 30.89% | 47.03% | $8.04 | $892.87 |
| 2026-10-29 | 30.89% | 47.03% | $8.04 | $897.85 |
| 2026-10-28 | 30.89% | 47.03% | $8.04 | $891.76 |
| 2026-10-27 | 30.80% | 47.08% | $8.04 | $882.48 |
| 2026-10-26 | 31.46% | 47.27% | $8.04 | $869.33 |
| 2026-10-23 | 31.19% | 47.67% | $7.91 | $873.71 |
| 2026-10-22 | 30.16% | 48.89% | $8.14 | $875.76 |
| 2026-10-21 | 32.60% | 50.21% | $7.98 | $890.05 |
| 2026-10-20 | 32.79% | 50.31% | $7.96 | $869.72 |
| 2026-10-19 | 32.77% | 50.15% | $7.93 | $825.61 |
| 2026-10-16 | 32.96% | 49.93% | $7.93 | $819.14 |
| 2026-10-15 | 32.96% | 49.93% | $7.93 | $846.27 |
| 2026-10-14 | 32.97% | 49.93% | $7.93 | $818.30 |
| 2026-10-13 | 33.19% | 50.04% | $7.90 | $802.64 |
| 2026-10-12 | 33.29% | 50.04% | $7.90 | $812.30 |
| 2026-10-11 | 32.79% | 50.04% | $7.90 | $825.03 |
| 2026-10-10 | 32.79% | 50.04% | $7.90 | $825.03 |
| 2026-10-09 | 32.79% | 50.04% | $7.90 | $825.03 |
| 2026-10-08 | 32.98% | 50.02% | $7.95 | $818.63 |
Reports Featuring ARGX
Recent News
- argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026GlobeNewswire
- Former Highflier Argenx Plummets On A Surprise Setback In Sjogren'sInvestor's Business Daily
- Former Highflier Argenx Plummets On A Surprise Setback In Sjogren'sInvestor's Business Daily
- IMVT, ROIV Stocks Slide As Argenx Sjögrens Trial Failure Hits Drug ClassStocktwits
- IMVT, ROIV Stocks Slide As Argenx Sjögrens Trial Failure Hits Drug ClassStocktwits
- Argenx Stock Sinks as Scrapped Vyvgart Trial Erases $3.5 Billion OpportunityBarrons.com
- Argenx Stock Sinks as Scrapped Vyvgart Trial Erases $3.5 Billion OpportunityBarrons.com
- argenx shares drop after trial of Vyvgart in Sjögren's disease is haltedProactive
- argenx shares drop after trial of Vyvgart in Sjögren's disease is haltedProactive
- Argenx falls as Sjögrens setback offsets celiac drug progressBioPharma Dive
Screen Performance
Aggregate stats across all 2145 tickers our top-EPS-revision screen has flagged over the past 225 days.
- Median return since detection
- -2.9%
- % of tickers in the green
- 43%
- Median return on winners
- +22.8%
- Large revisions captured
- 2246
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Argen X SE ADR's next-year EPS growth estimate?▾
As of 2026-11-12, Argen X SE ADR (ARGX) has a next-year EPS growth estimate of 36.04%, based on analyst consensus.
When was the latest EPS estimate revision for ARGX?▾
The most recent revision occurred on 2026-11-12, when analysts adjusted the next-year EPS growth estimate from 36.16% to 36.04%.
What sector and industry does Argen X SE ADR belong to?▾
Argen X SE ADR operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. ARGX appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Argen X SE ADR (ARGX) appears here because it was detected by our daily top-EPS-revision-performer screen.